Bloomsburg
Sign InJoin Now
AcquisitionJun 25, 2026Pending
🇺🇸 United States

Bio-Techne CorporationMerck KGaA, Darmstadt, Germany

Healthcare › Biotechnology

Enterprise value$11.3BEnterprise value
View SEC filing Save
AnnouncedJun 25, 2026
ConsiderationCash
StructureOne-step merger
RegionNorth America
Cross-borderYes
Contingent paymentNo

Overview

Merck KGaA, Darmstadt, Germany entered into a definitive merger agreement to acquire Bio-Techne for US$73 per share in cash, an enterprise value of about US$11.3 billion.

Deal rationale

The acquisition expands Merck KGaA's presence in high-growth life sciences markets such as multi-omics, spatial biology, and cell and gene therapy, with expected annual cost synergies of about EUR 140 million.

AI-generated from the SEC filing
PendingHealthcare › BiotechnologyUnited StatesNorth America

Timeline

  1. AnnouncedJun 25, 2026

    Imported from prototype record 332, unverified

    Filing
  2. Regulatory clearanceSep 18, 2026

    HSR waiting period expired or ended.

    Filing
  3. Shareholder vote · ApprovedSep 23, 2026

    Target shareholders approved the deal.

    Filing

Valuation and terms

Equity valueUndisclosed
Enterprise value$11.3BHeadline figure
ConsiderationCash

Advisors

Buy-side
GSGuggenheim SecuritiesJPJ.P. Morgan
Sell-side
GSGoldman Sachs

Parties

Target
Bio-Techne Corporation
Headquarters
United States
Ticker
TECH
EDGAR company page
Acquirer
Merck KGaA, Darmstadt, Germany
Headquarters
Germany
Ticker
—